BHARAT BIOTECH
Everyone who works at Tirumala should be Hindu, says newly-appointed chairman of TTD BR Naidu
B R Naidu, the new chairman of the Tirumala Tirupati Devasthanams (TTD) Board, has announced that his primary focus is to ensure that all staff working at Tirumala are Hindus. Naidu expressed his intent to address non-Hindu staff placement, potentially by relocating them to other government departments or providing a Voluntary Retirement Scheme (VRS).
RVNL, Mazagon Dock among 140 multibagger stocks with higher retail holding versus institutional
Over 140 stocks that have more retail holdings than institutional in the past year have delivered significant returns. Nine state-run companies and numerous private sector companies are among these multibaggers. Experts advise caution as many lesser-known stocks have liquidity risks. Some stocks like Kaycee Industries and Cropster Agro are recommended for exit.
Bharat Biotech inks pact with Alopexx for anti-microbial vaccine
Bharat Biotech has partnered with Alopexx, Inc. to co-develop and commercialize the anti-microbial vaccine AV0328 in India and other low-income countries. The collaboration aims to address antimicrobial resistance through vaccination, with Alopexx receiving upfront and milestone payments, as well as royalties on future sales in licensed territories.
Bharat Biotech launches oral cholera vaccine Hillchol after positive phase 3 trial
Bharat Biotech unveiled Hillchol, a new single-strain oral cholera vaccine, developed with Hilleman Laboratories. Addressing the high global demand for cholera vaccines, the company can produce up to 200 million doses annually. Phase 3 trials validated its safety and effectiveness. The vaccine is administered orally to individuals over one year old.
Trent shares rally 2% on Nifty inclusion next month
Trent Share Price: Tata's Trent shares rose 2% to Rs 7,090, hitting an all-time high, following its inclusion in the Nifty50 index. The stock is set for a $470 million inflow.
Bharat Biotech credited ICMR, NIV as Covaxin co-inventors after missing them initially: Government
Responding to Trinamool Congress member Sougata Roy, who had asked whether the government took any punitive action against the company for not mentioning the names of ICMR and NIV in the patent application, the Union Health and Family Welfare Minister gave a detailed reply. There was a joint Memorandum of Understanding (MoU) between ICMR, NIV and Bharat Biotech for the development of Covaxin, he said.
- Go To Page 1
Mankind trumps EQT-ADIA to buy BSV for $1.67 bn
This is the largest acquisition by Mankind Pharma, India¡¯s 4th largest pharma company by market share. A formal announcement regarding the deal is likely by this week.
Budget FY25: Pharmaceuticals sector needs a major boost with increased focus on R&D and innovation
The Union Budget 2024-2025, pivotal for India's Amrit Kaal vision, aims to foster economic growth and inclusive development. The budget is expected to boost infrastructure, streamline bureaucracy, and promote technology and innovation. Emphasis on the pharmaceutical sector, with increased allocations, can drive India's economic and healthcare advancements.
Mankind Pharma competes with EQT-ADIA combo for Rs 14,000 cr buyout of BSV Group from Advent
The buyout of BSV Group (formerly Bharat Serum & Vaccines Ltd) is contested by Mankind Pharma and EQT with ADIA, each offering around Rs 14,000 crore ($1.6 billion). This acquisition, one of India's largest pharma buyouts, will significantly impact the domestic market and mark a successful exit for Advent International.
Bharat Bio's Rotavirus vaccine Rotavac may be unsafe for children: Study
A study found that Bharat Biotech's Rotavac vaccine used in the government's immunization program increases the risk of intussusception in infants, a condition where the intestine telescopes into itself, leading to potential serious consequences.
ICMR distances itself from BHU's Covaxin study, asks to explain why it should not seek Iegal and administrative action
The Indian Council of Medical Research (ICMR) has criticised Banaras Hindu University (BHU) researchers for incorrectly associating them with an observational study on the side effects of Bharat Biotech's Covid-19 vaccine, Covaxin. The study, which covered a one-year period after the vaccine was administered, found that nearly a third of the 926 participants reported adverse events of special interest (AESI).
Covaxin demonstrated excellent safety record during studies: Bharat Biotech
Bharat Biotech asserted the safety of its Covid-19 vaccine, Covaxin, citing various studies published in peer-reviewed journals. This statement followed a report in The Economic Times regarding adverse events of special interest (AESI) reported by participants in an observational study on Covaxin. The company emphasized the need for comprehensive safety data in such studies, including comparisons with non-vaccinated subjects and those receiving other vaccines.
Covaxin side effects: What are the symptoms reported in adverse event cases? Should you worry?
Covaxin side effects: A recent study highlighted adverse events post-Bharat Biotech's Covaxin vaccinations. Led by Sankha Shubhra Chakrabarti, it noted higher risk in female adolescents and those with allergies. Of 1,024 participants, 47.9% adolescents and 42.6% adults reported viral infections. Common AESIs included skin disorders, menstrual abnormalities in females, and serious cases like stroke. Monitoring vaccinated individuals, especially those with prior Covid history, is crucial.
Adverse events seen in some participants who took Covaxin, reports new study
Covaxin Vaccine Side Effects: In an observational study on Bharat Biotech's Covaxin, nearly a third of participants reported adverse events of special interest (AESI), with females and those with allergies at higher risk. The majority of AESIs persisted at the 1-year follow-up. Common AESIs included viral upper respiratory tract infections, skin disorders, and nervous system issues. Serious AESIs like stroke and Guillain-Barre Syndrome were rare but reported. Females, adolescents, and those with pre-vaccination Covid-19 or comorbidities had higher odds of AESIs. Extended surveillance is recommended to understand late-onset adverse events.
Bharat Biotech says its Covaxin demonstrated ¡®excellent safety records¡¯
Bharat Biotech has emphasized the safety of its Covaxin Covid vaccine, stating that it has shown excellent safety records with no vaccine-associated incidents such as blood clots or other serious side effects. The company highlighted that Covaxin was developed with a focus on safety first, followed by efficacy. It mentioned that Covaxin was extensively evaluated in more than 27,000 subjects during its licensure process and has been continuously monitored for safety by the health ministry.
Bharat Biotech, Bilthoven Biologicals collaborate for oral polio vaccines production, supply
Bharat Biotech on Tuesday said it has collaborated with the Netherlands-based Bilthoven Biologicals B.V, a wholly-owned arm of Serum Institute of India, to strengthen production and supply security of oral polio vaccines. An agreement has been signed between the two partners under which Bharat Biotech will procure drug substances for the production of oral polio vaccines (OPVs) to be supplied within India and globally, the company said in a statement.
Bharat Biotech starts clinical trials of TB jab
The only vaccine in use today--BCG (Bacillus Calmette and Guerin)--is an attenuated variant of the bovine TB pathogen. This is more than a hundred years old and has a limited effect on pulmonary tuberculosis, which is mostly responsible for the transmission of the disease. Studying the safety, immunogenicity and efficacy of MTBVAC in the most populated country in the world and the one with the highest number of cases of this infectious disease is key to continue advancing in this vaccine," the company said.
Bharat Biotech begins clinical trials of TB vaccine on adults in India
Bharat Biotech International Ltd has initiated clinical trials for the Tuberculosis vaccine Mtbvac on adults in India. Developed by the Spanish biopharmaceutical company Biofabri, Mtbvac is the first TB vaccine derived from a human source. The vaccine aims to be more effective and longer-lasting than the current BCG vaccine for newborns and to prevent TB in adults and adolescents, for whom there is currently no effective vaccine. The trials are a significant step, especially in a country like India where 28% of the world's TB cases occur.
Bharat Biotech signs MoU with University of Sydney to collaborate on vaccine research
Bharat Biotech and the University of Sydney Infectious Diseases Institute (Sydney ID) have signed a memorandum of understanding to advance vaccine research initiatives and strengthen academic-industry partnerships. The collaboration aims to design novel methodologies for tackling future epidemics and infectious diseases, leveraging academia-industry strengths for vaccine and biotherapeutics advancement.
Bharat Biotech picks up 20 per cent stake in Eastman Exports Global Clothing
??A press release from Eastman Exports said it will use the new investment for capital expenditure, strengthening backward integration and customer acquisition among others. The funds will also help the company expand its presence in the global apparel industry, especially at a time when other countries are facing a slowdown and to capture the overall "China Plus One Strategy" of divesting manufacturing away from a single country.
Bharat Biotech's Krishna Ella suggests merging state drugs regulators with central body to ensure 'one quality one standard'
His comments came on Sunday in the backdrop of questions being raised about the quality of Indian drugs over the past few months. The latest instance was on Friday, when the Tamil Nadu-based Global Pharma Healthcare recalled its entire lot of eye drop linked allegedly to vision loss in the US.
Bharat Biotech founder bats for incentives, tax breaks for patented products, innovation
Speaking at the 72nd IPC in Nagpur earlier in the day, Drugs Controller General of India Dr V G Somani had said the Centre was all set to introduce a research linked incentive programme shaped on the lines of the production linked incentive (PLI) scheme to boost research and development of biotech products in the country.
Govt may not procure Bharat Biotech's intranasal Covid vaccine iNNOVACC
Bharat Biotech has made its intranasal Covid-19 vaccine iNNOVACC available on CoWin, priced at ?800 per dose for private markets and ?325 for the central and state governments. The intranasal vaccine will be rolled out as a booster dose in the fourth week of January for those above 18 years of age.
Ocugen-Bharat Biotech COVID vaccine meets main goals in U.S. trial
Covaxin is not cleared for use in any age group in the United States, but is one of the two most widely used COVID vaccines in India and has received emergency use listing from the World Health Organization (WHO). Ocugen did not provide details about its submission to the U.S. FDA for the vaccine. The company is responsible for conducting trials and commercialization of the shot in the United States under a partnership with Bharat Biotech.
Biological E, Bharat Biotech together sitting on stockpile of 250 million COVID vaccine doses
According to respective company sources, Biological E is holding 200 million doses of its COVID-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses of Covaxin. Dr Vikram Paradkar, Executive Vice President (Manufacturing), Biological E, said the firm produced about 30 crore doses of Corbevax in total, abiding by the vaccine manufacturing commitment to the Central government.
Private hospitals in talks with Bharat Biotech for intranasal Covid-19 vaccine
"We have written to Bharat Biotech, asking how we can procure the supply, about the pricing, etc," a senior executive at a private hospital said. "We are not sure about the demand yet, but in all probability, we will buy it in small quantities, just to be sure," the person told ET.
Bharat Biotech's intranasal Covid vaccine approved, to be available on CO-WIN from Friday
Bharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry for inclusion in the vaccination programme as a booster dose for those above 18 years of age, official sources said on Thursday. The needle-free vaccine will be available at private centres. It will be introduced on the Co-WIN platform on Friday evening, they said.
CCI approves Bharat Biotech International-Eastman Exports deal
The deal has been approved under the green channel route, wherein a transaction which does not raise any risk of an appreciable adverse effect on competition is deemed to be approved on it being intimated to the competition watchdog. In a release on the CCI's website, the fair trade regulator said it has approved the deal.
Bharat Biotech¡¯s intranasal vaccine ¡®iNCOVACC¡¯ receives CDSCO approval under restricted use
The Central Drugs Standard Control Organisation (CDSCO) gave its nod to the vaccine for use as both primary series as well as a heterologous booster.
Load More
